Monte Rosa Therapeutics, Inc. - Common Stock — Quarterly Financial Statistics (NASDAQ:GLUE) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Cash from operating activities -45.49 M-34.72 M100.43 M-43.01 M-37.37 M -14.68 M Cash from investing activities -100.23 M25.32 M38.14 M-65.07 M-261 M -262.6 M Cash from financing activities 14 K365 K348 K29.62 M328.33 M 358.67 M Free cash flow -45.49 M-34.72 M100.43 M-43.01 M-37.37 M -14.68 M

News

Monte Rosa: Initiating Coverage With A Buy On Degrader Platform Potential (NASDAQ:GLUE)

Monte Rosa Therapeutics (GLUE) Reports Q1 Loss, Misses Revenue Estimates

Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates

Monte Rosa Therapeutics, Inc. (GLUE) Presents at AACR Annual Meeting 2026 - Slideshow (NASDAQ:GLUE) 2026-04-23

Monte Rosa Therapeutics (GLUE) Reports Q4 Loss, Misses Revenue Estimates

Agenus (AGEN) Q4 Earnings and Revenues Surpass Estimates

Monte Rosa Therapeutics (GLUE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Monte Rosa Therapeutics earnings on deck amid revenue decline

Dunn Edmund, principal accounting officer, sells Monte Rosa (GLUE) shares for $2496

Kura Oncology (KURA) Reports Q4 Loss, Misses Revenue Estimates

Monte Rosa shares rise on prostate cancer trial results

Monte Rosa reports positive trial data for prostate cancer drug